Revision of PRECAUTIONS

Carboplatin

Aug 6, 2014

Non-proprietary Name

Carboplatin

Safety measure

Precautions should be revised in the package inserts.

In Clinically significant adverse reactions subsection of Adverse Reactions section, the following texts should be added:

**Tumour lysis syndrome:**

*Tumour lysis syndrome may occur.* Patients should be carefully monitored by checking serum electrolyte levels and renal function, etc. If any abnormalities are observed, administration of this drug should be discontinued, appropriate measures (e.g. administration of physiological saline solution and/or hyperuricaemia therapeutic agents, and dialysis) should be taken, and patients should be carefully monitored until recovery from such symptoms.

NOTE

- This drug is designated to prepare a Drug Guide for Patients.